

Strategic positioning of Galenica

Well prepared in a challenging market environment

Jean-Claude Clémençon CEO

Media and Analyst Conference, 12 March 2019

2018 in figures



Pleasing development in all Business sectors

Despite additional drug price reductions

→ Solid sales growth

→ Above-average EBIT growth

→ Dividend increase of 3%

Galenica Group:

In million CHF

Sales:

3,165.0

+ 0.8%

EBIT¹⁾:

154.1

+ 9.1%

Net profit¹⁾:

124.7

+ 9.5%

Dividend²⁾: CHF 1.70 per share

- 1) Comparable basis
- ²⁾ Proposal to the Annual General Meeting on 2 May 2019

GALENICA

Corporate Executive Committee

New Head Products & Brands (as of January 2019)





Felix Burkhard CFO



Daniele Madonna Head Retail



Thomas Szuran
Head Products & Brands



Christoph Amstutz
Head Services



New Chairwoman and strengthening of the Board of Directors


Daniela Bosshardt-Hengartner proposed for election as the new Chairwoman

- Pharmacist ETH
- Management consulting & finance
- Member of the Board of Directors since 2017

Markus R. Neuhaus proposed for election as a member of the Board of Directors

- PhD in law
- Certified tax expert
- Finance and business administration







Galenica is well prepared...









Galenica is well prepared



... and is a partner for all players in the healthcare market









Reliable partner for all market participants















Overcoming challenges

thanks to expansion, innovation and efficiency



Networked with all healthcare market players and across all channels



12.03.2019 © Galenica Group

8

Further progress on all three development axes


Expansion

Innovation

Efficiency











2018: 13 new pharmacies – 2 new online offerings

Over 500 points of sale!

Own pharmacies: 345

– Total network: > 500




Online offerings

- Careproduct
- Puresense






2019: further expansion and optimisation of the pharmacy network





2018: product portfolio and partnerships expanded



Product portfolio

- Algifor[®]
- Perskindol[®]
- Anti-Brumm[®]







New partnerships

- Spagyros
- Oenobiol







2019: develop partnerships and portfolio (from January 2019)





















Innovation






2018: Omni-Channel expanded

Online pharmacy

- All formats
- 40,000 products
- Incl. product information
- Know-how expansion






















Ambition: > 100,000 products



Innovation: supporting patients

GALENICA

Combine Omni-Channel!











Upload rec...

Find us


Promotions

Newsletter

Innovation: supporting patients

GALENICA

The right medicine at the right time in the right dosage



Innovation: health centre



Online services and prevention offerings















Upload rec...

Find us

Promotions Newsletter




Providing personal care to patients at home with new technologies

Mediservice personally cares for 10,000 patients

- At home
- By phone
- Via e-mail
- And now also with video therapy support













Efficiency





Retail: standardisation shows effect

- Triapharm[®]
- Central back office
- Direct invoicing



Generics substitution rate in Retail: 70%!



Efficiency



Services: investing in the future

New ERP solution at Alloga and Galexis

Modernisation of Galexis distribution centre at Lausanne-Ecublens

 Introduction of new blister machines at Medifilm

Solar energy production at Alloga



Galexis - Lausanne-Ecublens distribution centre



Alloga – largest solar installation in the Bern region




Regulatory and political environment





Authorities: measures and projects



¹⁾ Swissmedic categories C, D



Reduction of drug prices 2018 – 2020


in million CHF	Originally announced (average)	Subsequent increase	Effective savings 2018	Effective savings 2019	Effective savings 2020
2017	80	190	225		
2018	80	100	_	open	
2019	80	open	_	_	open
Total	240				

Source: Various press releases from the Federal Office of Public Health (FOPH)

GALENICA

Category change of OTC products Strengthening of the specialist retail trade

→ Less than 10% of products will leave the specialist retail trade!



Distribution margin – LOA V – Reference price system







2020


Generics prices
Amendment of Health
Insurance Act (KVG)

from 2021 ...



Overcoming challenges


thanks to expansion, innovation and efficiency



12.03.2019 © Galenica Group 3^o

We operate in a stable market environment

Development of the pharmaceutical market (excluding hospitals)



Source: IQVIA


Growth drivers

Population growth Over-65 Innovation Mew medications

Galenica: well prepared across all channels


Advice





Omni-Channel

Product range





Services